

## PRESS RELEASE



Inside information  
Regulated information

# ASIT biotech gp-ASIT+™ Phase III trial in grass pollen allergy did not meet the primary endpoint

Liège, Belgium, 25 November 2019, 7.00 am (CEST) – ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focusing on the research and development of breakthrough immunotherapy products for the treatment of allergies, announces results from a Phase III trial of its gp-ASIT+™ treatment in grass pollen allergy (gpASIT011).

The Phase III trial of gp-ASIT+™, an innovative immunotherapy treatment for grass pollen allergies which is administered in only three weeks prior to the grass pollen season, has randomized 650 patients from Belgium, Czech Republic, France, Germany, Hungary and Poland. The primary objective of the study is a 0.30 absolute reduction in the Combined Symptom and Medication Score (CSMS) in the treated group compared to placebo during the peak of the GP season. The study results showed a 0.15 (p=0.05) absolute reduction in the CSMS, during the peak of the GP season, and a 0.18 (p=0.005) absolute reduction in the CSMS during the entire GP season, translating into a treatment effect of 7.4% and 9.8% respectively vs. 20% expected.

**Michel Baijot, CEO of ASIT biotech, stated:** “Although the execution of the study was flawless and despite a good safety profile in line with previous results, these efficacy results are disappointing. As of 24<sup>th</sup> November 2019, the Company had a cash position of 3,8 Million Euro. We will analyze the data further and assess best options for the company on which we will communicate by year end.”

\*\*\*

### About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the research and development of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ - in ongoing phase III - and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

Further information can be found at [www.asitbiotech.com](http://www.asitbiotech.com).

Follow us on [LinkedIn](#)

## Contacts

### Company

Michel Baijot, CEO

ASIT biotech

Tel.: +32 2 264 03 90

[investors@asitbiotech.com](mailto:investors@asitbiotech.com)



### Investor Relations

LifeSci Advisors LLC

Hans Herklots

Tel.: +41 79 598 7149

[hherklots@lifesciadvisors.com](mailto:hherklots@lifesciadvisors.com)

### Media Relations

Sophie Baumont

Tel.: +33 627 74 74 49

[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)

## Legal notice

This announcement is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction. This announcement does not constitute a prospectus. Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be.

## Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guaranteeing future results. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.